Paper Details
- Home
- Paper Details
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Author: DienerHans-Christoph
Original Abstract of the Article :
Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year. In patients with TIA or ischemic stroke of non-cardiac origin, antiplatelet drugs are able to decrease the relative risk of stroke by 11-15% and the risk of stroke, myoca...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1111/j.1747-4949.2005.00016.x
データ提供:米国国立医学図書館(NLM)
Secondary Stroke Prevention with Antiplatelet Drugs: Have We Reached the Ceiling?
Stroke is a serious condition that can have devastating consequences. This study investigates the effectiveness of antiplatelet drugs in preventing recurrent strokes in patients who have experienced a transient ischemic attack (TIA) or ischemic stroke. Researchers review existing studies on the use of antiplatelet drugs, including aspirin, dipyridamole, clopidogrel, and GP IIb/IIIa antagonists. They analyze the relative risks and benefits of each drug and discuss the optimal selection of antiplatelet therapy for stroke prevention.
Antiplatelet Drugs: A Crucial Tool in Stroke Prevention
This study underscores the importance of antiplatelet drugs in reducing the risk of recurrent strokes. The researchers demonstrate that aspirin is highly effective and affordable, while the combination of aspirin with dipyridamole offers further benefits. They also highlight the potential benefits of clopidogrel in high-risk patients. However, the study cautions against using more potent drugs than aspirin unless the patient is at particularly high risk of recurrence, as these drugs carry a greater risk of bleeding complications. It's like carefully navigating a treacherous landscape, where each step must be well-considered.
Choosing the Right Path: Individualized Stroke Prevention
This study emphasizes the need for individualized approaches to stroke prevention. The researchers highlight the importance of carefully evaluating patient characteristics, such as risk factors, previous stroke history, and potential drug interactions, before selecting the most appropriate antiplatelet therapy. It's like choosing the right path in a vast desert, ensuring that it leads to a safe and healthy destination.
Dr. Camel's Conclusion
This study provides valuable guidance on the use of antiplatelet drugs for secondary stroke prevention. The findings underscore the need for a careful balance between the benefits and risks of these drugs. It's like finding a delicate equilibrium in the desert, where the benefits of shade and water must be weighed against the dangers of sandstorms and dehydration.
Date :
- Date Completed 2008-11-18
- Date Revised 2018-12-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.